Daniel Wiseman, MBChB, MRCP, FRCPath, PhD, University of Manchester, Manchester, UK, comments on emerging therapeutic strategies in chronic myelomonocytic leukemia (CMML). The recent approval of oral decitabine and cedazuridine (ASTX727) in the US is expected to significantly improve the quality of life (QoL) of patients with CMML. This combination has not yet been approved in the UK, but it is soon going to be assessed in the AMMO trial. Ongoing studies are evaluating ruxolitinib, lenzilumab, and drugs targeting splicing. In addition, evidence has suggested the MAPK/ERK signaling pathway as a promising therapeutic target for CMML. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.

свернуть